Total Payments
$141,397
2024 Payments
$11,585
Companies
42
Transactions
744
Medicare Patients
22,099
Medicare Billing
$10.5M
Payment Breakdown by Category
Research$110,845 (78.4%)
Food & Beverage$22,027 (15.6%)
Consulting$6,987 (4.9%)
Travel$1,119 (0.8%)
Other$359.61 (0.3%)
Gifts$45.00 (0.0%)
Education$14.13 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $110,845 | 15 | 78.4% |
| Food and Beverage | $22,027 | 715 | 15.6% |
| Consulting Fee | $6,987 | 5 | 4.9% |
| Travel and Lodging | $1,119 | 3 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $279.87 | 1 | 0.2% |
| Entertainment | $55.56 | 1 | 0.0% |
| Gift | $45.00 | 1 | 0.0% |
| Honoraria | $24.18 | 2 | 0.0% |
| Education | $14.13 | 1 | 0.0% |
Payments by Type
Research
$110,845
15 transactions
General
$30,552
729 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Hexal AG | $70,540 | 8 | $0 (2023) |
| Alimera Sciences, Inc. | $28,297 | 53 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $11,937 | 27 | $0 (2024) |
| Allergan, Inc. | $6,116 | 88 | $0 (2022) |
| Amgen Inc. | $3,932 | 2 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $2,441 | 18 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $2,039 | 106 | $0 (2023) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,585 | 71 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $1,573 | 36 | $0 (2024) |
| Genentech USA, Inc. | $1,438 | 56 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,585 | 136 | Amgen Inc. ($3,932) |
| 2023 | $16,772 | 106 | EyePoint Pharmaceuticals US, Inc. ($9,690) |
| 2022 | $38,020 | 104 | Hexal AG ($35,400) |
| 2021 | $33,716 | 130 | Hexal AG ($31,139) |
| 2020 | $1,794 | 72 | Allergan, Inc. ($563.45) |
| 2019 | $2,402 | 64 | Bausch & Lomb, a division of Bausch Health US, LLC ($592.01) |
| 2018 | $10,687 | 59 | Alimera Sciences, Inc. ($5,655) |
| 2017 | $26,421 | 73 | Alimera Sciences, Inc. ($19,784) |
All Payment Transactions
744 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: Ophthalmology | ||||||
| 12/18/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Dry eyes | ||||||
| 12/18/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $2.55 | General |
| Category: Ophthalmology | ||||||
| 12/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | Cash or cash equivalent | $186.26 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 12/13/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 12/12/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $28.36 | General |
| Category: Ophthalmology | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: Ophthalmology | ||||||
| 12/10/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: Ophthalmology | ||||||
| 12/04/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Dry eyes | ||||||
| 12/04/2024 | Alcon Vision LLC | Rocklatan (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Ophthalmology | ||||||
| 11/27/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $28.63 | General |
| Category: Ophthalmology | ||||||
| 11/26/2024 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: EYE CARE | ||||||
| 11/21/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $6.47 | General |
| Category: Ophthalmology | ||||||
| 11/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $28.25 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $466.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $466.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $367.65 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $218.68 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/14/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $12.98 | General |
| Category: Dry eyes | ||||||
| 11/13/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Ophthalmology | ||||||
| 11/13/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug) | Food and Beverage | In-kind items and services | $8.70 | General |
| Category: Ophthalmology | ||||||
| 11/07/2024 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $34.03 | General |
| Category: EYE CARE | ||||||
| 11/07/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $5.90 | General |
| Category: Ophthalmology | ||||||
| 11/06/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: Ophthalmology | ||||||
| 11/05/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CSOK583A12301 | Hexal AG | $70,540 | 8 |
| PALADIN | Alimera Sciences, Inc. | $25,190 | 3 |
| A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD | EyePoint Pharmaceuticals US, Inc. | $9,405 | 1 |
| A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration | Allergan Inc. | $3,887 | 2 |
| Iluvien Study | Alimera Sciences, Inc. | $1,824 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 5,480 | 73,379 | $6.5M | $3.4M |
| 2022 | 23 | 5,040 | 20,872 | $5.2M | $2.4M |
| 2021 | 24 | 6,103 | 16,809 | $4.9M | $2.3M |
| 2020 | 23 | 5,476 | 16,791 | $5.1M | $2.4M |
Total Patients
22,099
Total Services
127,851
Medicare Billing
$10.5M
Procedure Codes
95
All Medicare Procedures & Services
95 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 128 | 56,580 | $2.3M | $1.6M | 72.6% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,067 | 3,758 | $751,600 | $404,064 | 53.8% |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | Office | 2023 | 58 | 1,495 | $448,500 | $255,054 | 56.9% |
| 67028 | Injection of drug into eye | Office | 2023 | 339 | 2,407 | $890,590 | $236,913 | 26.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 69 | 1,114 | $501,300 | $199,773 | 39.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 40 | 296 | $355,200 | $192,098 | 54.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 551 | 708 | $157,884 | $85,154 | 53.9% |
| 92134 | Imaging of retina | Office | 2023 | 638 | 2,294 | $229,350 | $79,784 | 34.8% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 16 | 495 | $99,000 | $59,579 | 60.2% |
| 92242 | Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2023 | 151 | 230 | $92,023 | $53,754 | 58.4% |
| 92250 | Photography of the retina | Office | 2023 | 1,074 | 1,833 | $233,034 | $51,389 | 22.1% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 158 | 662 | $132,400 | $48,262 | 36.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 251 | 251 | $56,224 | $31,186 | 55.5% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 13 | 161 | $37,030 | $25,303 | 68.3% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 25 | 39 | $46,800 | $16,665 | 35.6% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 211 | 222 | $27,528 | $10,616 | 38.6% |
| 92274 | Measurement of retinal and optic nerve function targeting multiple separate locations | Office | 2023 | 124 | 128 | $31,360 | $9,771 | 31.2% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 249 | 360 | $18,000 | $7,627 | 42.4% |
| 92273 | Measurement of retinal and optic nerve function | Office | 2023 | 52 | 53 | $13,250 | $5,811 | 43.9% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 54 | 54 | $5,832 | $3,966 | 68.0% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 15 | 17 | $42,500 | $3,402 | 8.0% |
| 92133 | Imaging of optic nerve | Office | 2023 | 103 | 108 | $8,100 | $3,074 | 37.9% |
| 95930 | Measurement of nerve conduction using visual stimulation testing with report | Office | 2023 | 39 | 41 | $9,840 | $2,492 | 25.3% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 38 | 55 | $12,925 | $2,137 | 16.5% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 17 | 18 | $2,286 | $835.89 | 36.6% |
About Dr. Kent Small, MD
Dr. Kent Small, MD is a Retina Specialist healthcare provider based in Glendale, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861470783.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kent Small, MD has received a total of $141,397 in payments from pharmaceutical and medical device companies, with $11,585 received in 2024. These payments were reported across 744 transactions from 42 companies. The most common payment nature is "" ($110,845).
As a Medicare-enrolled provider, Small has provided services to 22,099 Medicare beneficiaries, totaling 127,851 services with total Medicare billing of $10.5M. Data is available for 4 years (2020–2023), covering 95 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Glendale, CA
- Active Since 01/03/2006
- Last Updated 04/12/2023
- Taxonomy Code 207WX0107X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1861470783
Products in Payments
- ILUVIEN (Biological) $19,690
- EYP-1901 $9,527
- Iluvien (Drug) $6,319
- LUMAKRAS (Drug) $3,932
- XIIDRA (Drug) $2,496
- ACTHAR (Biological) $2,441
- ILUVIEN (Drug) $2,076
- EYP-1901 (Drug) $1,819
- Cequa (Drug) $1,371
- DURYSTA (Drug) $1,094
- TYRVAYA (Drug) $932.01
- EVA Ophthalmic Surgical System (Device) $850.00
- MIEBO (Drug) $786.92
- EYLEA (Biological) $717.48
- Lucentis (Biological) $659.56
- Izervay (Drug) $616.01
- Syfovre (Drug) $573.06
- Vabysmo (Drug) $533.74
- EYLEA AFLIBERCEPT INJECTION (Biological) $432.03
- EYLEA HD (Biological) $423.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.